| 1 |
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A．Global cancer statistics，2012[J]．CA Cancer J Clin，2015，65(2):87-108.
|
| 2 |
Zhou M, Wang H, Zeng X，et al.Mortality，morbidity，and risk factors in China and its provinces，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017[J]．Lancet，2019，394(10204):1145-58.
|
| 3 |
Zhang BH, Yang BH, Tang ZY.Randomized controlled trial of screening for hepatocellular carcinoma[J]．J Cancer Res Clin Oncol，2004，130(7):417-22.
|
| 4 |
Dong Y, Wang WP, Mao F, Ji ZB, Huang BJ.Application of imaging fusion combining contrast-enhanced ultrasound and magnetic resonance imaging in detection of hepatic cellular carcinomas undetectable by conventional ultrasound[J]．J Gastroenterol Hepatol，2016，31(4):822-8.
|
| 5 |
Da Silva NPB, Hornung M, Beyer LP，et al.Intraoperative Shear Wave Elastography vs.Contrast-Enhanced Ultrasound for the Characterization and Differentiation of Focal Liver Lesions to Optimize Liver Tumor Surgery[J]．Ultraschall Med，2019，40(2):205-11.
|
| 6 |
Hu H, Han H, Han XK, Wang WP, Ding H．Nomogram for individualised prediction of liver failure risk after hepatectomy in patients with resectable hepatocellular carcinoma：the evidence from ultrasound data[J]．Eur Radiol，2018，28(2):877-85.
|
| 7 |
Grgurevic I, Bokun T, Salkic NN，et al.Liver elastography malignancy prediction score for noninvasive characterization of focal liver lesions[J]．Liver Int，2018，38(6):1055-63.
|
| 8 |
Berzigotti A, Ferraioli G, Bota S, Gilja OH, Dietrich CF.Novel ultrasound-based methods to assess liver disease：The game has just begun[J]．Dig Liver Dis，2018，50(2):107-12.
|
| 9 |
Lee YJ, Lee JM, Lee JS，et al.Hepatocellular carcinoma：diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis[J]．Radiology，2015，275(1):97-109.
|
| 10 |
Liu X, Jiang H, Chen J, Zhou Y, Huang Z, Song B．Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma：A meta-analysis[J]．Liver Transpl，2017，23(12):1505-18.
|
| 11 |
Zeng MS, Ye HY, Guo L，et al.Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patients：a multicenter，open-label，phase Ⅲ study[J]．Hepatobiliary Pancreat Dis Int，2013，12(6):607-16.
|
| 12 |
Ichikawa T, Saito K, Yoshioka N，et al.Detection and characterization of focal liver lesions：a Japanese phase Ⅲ，multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease[J]．Invest Radiol，2010，45(3):133-41.
|
| 13 |
丁莺，陈财忠，饶圣祥，等．Gd＋-EOB-DTPA与Gd＋-DTPA增强磁共振检查肝细胞癌的对照研究[J]．中华普通外科杂志，2013，28(9):682-85.
|
| 14 |
Yoo SH, Choi JY, Jang JW，et al.Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma[J]．Ann Surg Oncol，2013，20(9):2893-900.
|
| 15 |
Rao SX, Wang J, Wang J，et al.Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agent：Gadoxetic acid disodium[J]．J Dig Dis，2019，20(2):54-61.
|
| 16 |
Marrero JA, Kulik LM, Sirlin CB，et al.Diagnosis，Staging，and Management of Hepatocellular Carcinoma：2018 Practice Guidance by the American Association for the Study of Liver Diseases[J]．Hepatology，2018，68(2):723-50.
|
| 17 |
EASL Clinical Practice Guidelines：Management of hepatocellular carcinoma[J]．J Hepatol，2018，69(1):182-236.
|
| 18 |
Omata M, Cheng AL, Kokudo N，et al.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma：a 2017 update[J]．Hepatol Int，2017，11(4):317-70.
|
| 19 |
Cho ES, Choi JY.MRI features of hepatocellular carcinoma related to biologic behavior[J]．Korean J Radiol，2015，16(3):449-64.
|
| 20 |
Hwang J, Kim YK, Jeong WK, Choi D, Rhim H, Lee WJ.Nonhypervascular Hypointense Nodules at Gadoxetic Acid-enhanced MR Imaging in Chronic Liver Disease：Diffusion-weighted Imaging for Characterization[J]．Radiology，2015，276(1):137-46.
|
| 21 |
Renzulli M, Biselli M, Brocchi S，et al.New hallmark of hepatocellular carcinoma，early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis：a new diagnostic algorithm[J]．Gut，2018，67(9):1674-82.
|
| 22 |
Xu X, Zhang HL, Liu QP，et al.Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma[J]．J Hepatol，2019，70(6):1133-44.
|
| 23 |
Lei Z, Li J, Wu D，et al.Nomogram for Preoperative Estimation of Microvascular Invasion Risk in Hepatitis B Virus-Related Hepatocellular Carcinoma Within the Milan Criteria[J]．JAMA Surg，2016，151(4):356-63.
|
| 24 |
Peng J, Zhang J, Zhang Q, Xu Y, Zhou J, Liu L．A radiomics nomogram for preoperative prediction of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma[J]．Diagn Interv Radiol，2018，24(3):121-27.
|
| 25 |
Park JW, Kim JH, Kim SK，et al.A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma[J]．J Nucl Med，2008，49(12):1912-21.
|
| 26 |
Lin CY, Chen JH, Liang JA, Lin CC, Jeng LB, Kao CH.18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma：a systematic review and meta-analysis[J]．Eur J Radiol，2012，81(9):2417-22.
|
| 27 |
Boellaard R, Delgado-Bolton R, Oyen WJ，et al.FDG PET/CT：EANM procedure guidelines for tumour imaging：version 2.0[J]．Eur J Nucl Med Mol Imaging，2015，42(2):328-54.
|
| 28 |
Boellaard R, O′doherty MJ, Weber WA，et al.FDG PET and PET/CT：EANM procedure guidelines for tumour PET imaging：version 1.0[J]．Eur J Nucl Med Mol Imaging，2010，37(1):181-200.
|
| 29 |
Wahl RL, Jacene H, Kasamon Y, Lodge MA.From RECIST to PERCIST：Evolving Considerations for PET response criteria in solid tumors[J]．J Nucl Med，2009，50 Suppl 1:122S-50S.
|
| 30 |
Chalian H, Tore HG, Horowitz JM, Salem R, Miller FH, Yaghmai V．Radiologic assessment of response to therapy：comparison of RECIST Versions 1.1 and 1.0[J]．Radiographics，2011，31(7):2093-105.
|
| 31 |
Ferda J, Ferdova E, Baxa J，et al.The role of 18F-FDG accumulation and arterial enhancement as biomarkers in the assessment of typing，grading and staging of hepatocellular carcinoma using 18F-FDG-PET/CT with integrated dual-phase CT angiography[J]．Anticancer Res，2015，35(4):2241-6.
|
| 32 |
Lee JW, Oh JK, Chung YA，et al.Prognostic Significance of 18F-FDG Uptake in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization or Concurrent Chemoradiotherapy：A Multicenter Retrospective Cohort Study[J]．J Nucl Med，2016，57(4):509-16.
|
| 33 |
Hyun SH, Eo JS, Lee JW，et al.Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas：a multicenter retrospective cohort study[J]．Eur J Nucl Med Mol Imaging，2016，43(9):1638-45.
|
| 34 |
Na SJ, Oh JK, Hyun SH，et al.(18)F-FDG PET/CT Can Predict Survival of Advanced Hepatocellular Carcinoma Patients：A Multicenter Retrospective Cohort Study[J]．J Nucl Med，2017，58(5):730-36.
|
| 35 |
Bertagna F, Bertoli M, Bosio G，et al.Diagnostic role of radiolabelled choline PET or PET/CT in hepatocellular carcinoma：a systematic review and meta-analysis[J]．Hepatol Int，2014，8(4):493-500.
|
| 36 |
Cheung TT, Ho CL, Lo CM，et al.11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria：surgeon′s perspective[J]．J Nucl Med，2013，54(2):192-200.
|
| 37 |
Zhang Y, Shi H, Cheng D，et al.Added value of SPECT/spiral CT versus SPECT in diagnosing solitary spinal lesions in patients with extraskeletal malignancies[J]．Nucl Med Commun，2013，34(5):451-8.
|
| 38 |
Hectors SJ, Wagner M, Besa C, Huang W, Taouli B．Multiparametric FDG-PET/MRI of Hepatocellular Carcinoma：Initial Experience[J]．Contrast Media Mol Imaging，2018，2018:5638283.
|
| 39 |
Forner A, Vilana R, Ayuso C，et al.Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis：Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma[J]．Hepatology，2008，47(1):97-104.
|
| 40 |
Roberts LR, Sirlin CB, Zaiem F，et al.Imaging for the diagnosis of hepatocellular carcinoma：A systematic review and meta-analysis[J]．Hepatology，2018，67(1):401-21.
|
| 41 |
Paradish V，Fukayama M，Park YN，Schirmacher P：Tumors of the liver and intrahepatic bile ducts，Board W C O T E，editor，WHO Classification of Tumours of the Digestive System：World Health Organization Press，2019.
|
| 42 |
Zhou J, Yu L, Gao X，et al.Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]．J Clin Oncol，2011，29(36):4781-8.
|
| 43 |
Westra WH, Hruban RH, Phelps TH, Isacson C．Surgical Pathology Dissection：An Illustrated Guide[M]．New York：Springer，2003：258.
|
| 44 |
Nara S, Shimada K, Sakamoto Y，et al.Prognostic impact of marginal resection for patients with solitary hepatocellular carcinoma：evidence from 570 hepatectomies[J]．Surgery，2012，151(4):526-36.
|
| 45 |
丛文铭．肝胆肿瘤外科病理学[M]．北京：人民卫生出版社，2015：276-320.
|
| 46 |
Scheuer PJ.Classification of chronic viral hepatitis：a need for reassessment[J]．J Hepatol，1991，13(3):372-4.
|
| 47 |
病毒性肝炎防治方案[J]．中华传染病杂志，2001，19(1):56-62.
|
| 48 |
Lasser C．Exosomes in diagnostic and therapeutic applications：biomarker，vaccine and RNA interference delivery vehicle[J]．Expert Opin Biol Ther，2015，15(1):103-17.
|
| 49 |
Rodriguez-Peralvarez M, Luong TV, Andreana L, Meyer T, Dhillon AP, Burroughs AK.A systematic review of microvascular invasion in hepatocellular carcinoma：diagnostic and prognostic variability[J]．Ann Surg Oncol，2013，20(1):325-39.
|
| 50 |
中国抗癌协会肝癌专业委员会，中华医学会肝病学分会肝癌学组，中国抗癌协会病理专业委员会，等．原发性肝癌规范化病理诊断指南(2015年版)[J]．中华肝胆外科杂志，2015，21(3):145-51.
|
| 51 |
Eguchi S, Takatsuki M, Hidaka M，et al.Predictor for histological microvascular invasion of hepatocellular carcinoma：a lesson from 229 consecutive cases of curative liver resection[J]．World J Surg，2010，34(5):1034-8.
|
| 52 |
Fujita N, Aishima S, Iguchi T，et al.Histologic classification of microscopic portal venous invasion to predict prognosis in hepatocellular carcinoma[J]．Hum Pathol，2011，42(10):1531-8.
|
| 53 |
Iguchi T, Shirabe K, Aishima S，et al.New Pathologic Stratification of Microvascular Invasion in Hepatocellular Carcinoma：Predicting Prognosis After Living-donor Liver Transplantation[J]．Transplantation，2015，99(6):1236-42.
|
| 54 |
Shi L, Zhang SJ, Chen J，et al.A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma[J]．Mod Pathol，2019.
|
| 55 |
Xie DY, Fan HK, Ren ZG, Fan J, Gao Q．Identifying Clonal Origin of Multifocal Hepatocellular Carcinoma and Its Clinical Implications[J]．Clin Transl Gastroenterol，2019，10(2):e00006.
|
| 56 |
Wen T, Jin C, Facciorusso A，et al.Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection：an international expert consensus[J]．Hepatobiliary Surg Nutr，2018，7(5):353-71.
|
| 57 |
Wang B, Xia CY, Lau WY，et al.Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation：a new strategy for hepatic surgery[J]．J Am Coll Surg，2013，217(6):1054-62.
|
| 58 |
Cong WM, Wu MC.New insights into molecular diagnostic pathology of primary liver cancer：Advances and challenges[J]．Cancer Lett，2015，368(1):14-19.
|
| 59 |
Imamura H, Seyama Y, Kokudo N，et al.One thousand fifty-six hepatectomies without mortality in 8 years[J]．Arch Surg，2003，138(11):1198-206;discussion 206.
|
| 60 |
Kubota K, Makuuchi M, Kusaka K，et al.Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors[J]．Hepatology，1997，26(5):1176-81.
|
| 61 |
Bruix J, Castells A, Bosch J，et al.Surgical resection of hepatocellular carcinoma in cirrhotic patients：prognostic value of preoperative portal pressure[J]．Gastroenterology，1996，111(4):1018-22.
|
| 62 |
Cescon M, Colecchia A, Cucchetti A，et al.Value of transient elastography measured with FibroScan in predicting the outcome of hepatic resection for hepatocellular carcinoma[J]．Ann Surg，2012，256(5):706-12;discussion 12-3.
|
| 63 |
Shen Y, Zhou C, Zhu G，et al.Liver Stiffness Assessed by Shear Wave Elastography Predicts Postoperative Liver Failure in Patients with Hepatocellular Carcinoma[J]．J Gastrointest Surg，2017，21(9):1471-79.
|
| 64 |
Rajakannu M, Cherqui D, Ciacio O，et al.Liver stiffness measurement by transient elastography predicts late posthepatectomy outcomes in patients undergoing resection for hepatocellular carcinoma[J]．Surgery，2017，162(4):766-74.
|
| 65 |
Zhong JH, Ke Y, Gong WF，et al.Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma[J]．Ann Surg，2014，260(2):329-40.
|
| 66 |
Xiao H, Zhang B, Mei B，et al.Hepatic resection for hepatocellular carcinoma in patients with portal hypertension：a long-term benefit compared with transarterial chemoembolization and thermal ablation[J]．Medicine(Baltimore)，2015，94(7):e495.
|
| 67 |
Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC.The clinical use of HVPG measurements in chronic liver disease[J]．Nat Rev Gastroenterol Hepatol，2009，6(10):573-82.
|
| 68 |
Chen X, Zhai J, Cai X，et al.Severity of portal hypertension and prediction of postoperative liver failure after liver resection in patients with Child-Pugh grade A cirrhosis[J]．Br J Surg，2012，99(12):1701-10.
|
| 69 |
Chen MS, Li JQ, Zheng Y，et al.A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma[J]．Ann Surg，2006，243(3):321-8.
|
| 70 |
Mohkam K, Dumont PN, Manichon AF，et al.No-touch multibipolar radiofrequency ablation vs.surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5cm[J]．J Hepatol，2018，68(6):1172-80.
|
| 71 |
Liu PH, Hsu CY, Hsia CY，et al.Surgical Resection Versus Radiofrequency Ablation for Single Hepatocellular Carcinoma</＝2 cm in a Propensity Score Model[J]．Ann Surg，2016，263(3):538-45.
|
| 72 |
Feng K, Yan J, Li X，et al.A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma[J]．J Hepatol，2012，57(4):794-802.
|
| 73 |
Xu Q, Kobayashi S, Ye X, Meng X．Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma：a meta-analysis of 16，103 patients[J]．Sci Rep，2014，4:7252.
|
| 74 |
Yin L, Li H, Li AJ，et al.Partial hepatectomy vs.transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria：a RCT[J]．J Hepatol，2014，61(1):82-8.
|
| 75 |
Torzilli G, Belghiti J, Kokudo N，et al.A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers：is it adherent to the EASL/AASLD recommendations？：an observational study of the HCC East-West study group[J]．Ann Surg，2013，257(5):929-37.
|
| 76 |
Wang K, Guo WX, Chen MS，et al.Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus：A Large-Scale，Multicenter，Propensity Mathching Score Analysis[J]．Medicine(Baltimore)，2016，95(11):e3015.
|
| 77 |
Wei X, Jiang Y, Zhang X，et al.Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus：A Randomized，Open-Label，Multicenter Controlled Study[J]．J Clin Oncol，2019:Jco1802184.
|
| 78 |
Li XL, Zhu XD, Cai H，et al.Postoperative alpha-fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma：A propensity score matching analysis[J]．Surgery，2019，165(6):1161-67.
|
| 79 |
Yang J, Tao HS, Cai W，et al.Accuracy of actual resected liver volume in anatomical liver resections guided by 3-dimensional parenchymal staining using fusion indocyanine green fluorescence imaging[J]．J Surg Oncol，2018，118(7):1081-87.
|
| 80 |
Mise Y, Hasegawa K, Satou S，et al.How Has Virtual Hepatectomy Changed the Practice of Liver Surgery？：Experience of 1194 Virtual Hepatectomy Before Liver Resection and Living Donor Liver Transplantation[J]．Ann Surg，2018，268(1):127-33.
|
| 81 |
Jiang HT, Cao JY.Impact of laparoscopic versus open hepatectomy on perioperative clinical outcomes of patients with primary hepatic carcinoma[J]．Chin Med Sci J，2015，30(2):80-3.
|
| 82 |
Wu X, Huang Z, Lau WY，et al.Perioperative and long-term outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with well-preserved liver function and cirrhotic background：a propensity score matching study[J]．Surg Endosc，2019，33(1):206-15.
|
| 83 |
Cheung TT, Han HS, She WH，et al.The Asia Pacific Consensus Statement on Laparoscopic Liver Resection for Hepatocellular Carcinoma：A Report from the 7th Asia-Pacific Primary Liver Cancer Expert Meeting Held in Hong Kong[J]．Liver Cancer，2018，7(1):28-39.
|
| 84 |
Shi M, Guo RP, Lin XJ，et al.Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma：a prospective randomized trial[J]．Ann Surg，2007，245(1):36-43.
|
| 85 |
Yang P, Si A, Yang J，et al.A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion[J]．Surgery，2019，165(4):721-30.
|
| 86 |
Liu CL, Fan ST, Lo CM, Tung-Ping Poon R, Wong J．Anterior approach for major right hepatic resection for large hepatocellular carcinoma[J]．Ann Surg，2000，232(1):25-31.
|
| 87 |
Zhou C, Peng Y, Zhou K，et al.Surgical resection plus radiofrequency ablation for the treatment of multifocal hepatocellular carcinoma[J]．Hepatobiliary Surg Nutr，2019，8(1):19-28.
|
| 88 |
Zhang ZM, Lai EC, Zhang C，et al.The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus[J]．Int J Surg，2015，20:8-16.
|
| 89 |
Fu SY, Lau WY, Li AJ，et al.Liver resection under total vascular exclusion with or without preceding Pringle manoeuvre[J]．Br J Surg，2010，97(1):50-5.
|
| 90 |
Satoh S, Ikai I, Honda G，et al.Clinicopathologic evaluation of hepatocellular carcinoma with bile duct thrombi[J]．Surgery，2000，128(5):779-83.
|
| 91 |
Tang ZY, Uy YQ, Zhou XD，et al.Cytoreduction and sequential resection for surgically verified unresectable hepatocellular carcinoma：evaluation with analysis of 72 patients[J]．World J Surg，1995，19(6):784-9.
|
| 92 |
Tang ZY, Yu YQ, Zhou XD，et al.Treatment of unresectable primary liver cancer：with reference to cytoreduction and sequential resection[J]．World J Surg，1995，19(1):47-52.
|
| 93 |
Wakabayashi H, Okada S, Maeba T, Maeta H．Effect of preoperative portal vein embolization on major hepatectomy for advanced-stage hepatocellular carcinomas in injured livers：a preliminary report[J]．Surg Today，1997，27(5):403-10.
|
| 94 |
Ogata S, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V．Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma[J]．Br J Surg，2006，93(9):1091-8.
|
| 95 |
Wang Z, Peng Y, Hu J，et al.Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy for Unresectable Hepatitis B Virus-related Hepatocellular Carcinoma：A Single Center Study of 45 Patients[J]．Ann Surg，2018.
|
| 96 |
D′haese JG, Neumann J, Weniger M，et al.Should ALPPS be Used for Liver Resection in Intermediate-Stage HCC？[J]．Ann Surg Oncol，2016，23(4):1335-43.
|
| 97 |
郑树国，李建伟，肖乐，曹利，郭鹏．全腹腔镜联合肝脏离断和门静脉结扎的二步肝切除术治疗肝硬化肝癌[J]．中华消化外科杂志，2014，13(7):502-07.
|
| 98 |
Hong De F, Zhang YB, Peng SY, Huang DS.Percutaneous Microwave Ablation Liver Partition and Portal Vein Embolization for Rapid Liver Regeneration：A Minimally Invasive First Step of ALPPS for Hepatocellular Carcinoma[J]．Ann Surg，2016，264(1):e1-2.
|
| 99 |
Shi HY, Wang SN, Wang SC, Chuang SC, Chen CM, Lee KT.Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma：a nationwide Taiwan database analysis of long-term outcome predictors[J]．J Surg Oncol，2014，109(5):487-93.
|
| 100 |
Zhou WP, Lai EC, Li AJ，et al.A prospective，randomized，controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma[J]．Ann Surg，2009，249(2):195-202.
|
| 101 |
Yin J, Li N, Han Y，et al.Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma：a two-stage longitudinal clinical study[J]．J Clin Oncol，2013，31(29):3647-55.
|
| 102 |
Huang G, Lau WY, Wang ZG，et al.Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma：a randomized controlled trial[J]．Ann Surg，2015，261(1):56-66.
|
| 103 |
Wang Z, Ren Z, Chen Y，et al.Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection：A Randomized Controlled Study[J]．Clin Cancer Res，2018，24(9):2074-81.
|
| 104 |
Wei W, Jian PE, Li SH，et al.Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion：a randomized clinical trial of efficacy and safety[J]．Cancer Commun(Lond)，2018，38(1):61.
|
| 105 |
Chen Q, Shu C, Laurence AD，et al.Effect of Huaier granule on recurrence after curative resection of HCC：a multicentre，randomised clinical trial[J]．Gut，2018，67(11):2006-16.
|
| 106 |
Huang G, Li PP, Lau WY，et al.Antiviral Therapy Reduces Hepatocellular Carcinoma Recurrence in Patients With Low HBV-DNA Levels：A Randomized Controlled Trial[J]．Ann Surg，2018，268(6):943-54.
|
| 107 |
Fan J, Zhou J, Wu ZQ，et al.Efficacy of different treatment strategies for hepatocellular carcinoma with portal vein tumor thrombosis[J]．World J Gastroenterol，2005，11(8):1215-9.
|
| 108 |
Lo CM, Liu CL, Chan SC，et al.A randomized，controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma[J]．Ann Surg，2007，245(6):831-42.
|
| 109 |
Sun HC, Tang ZY, Wang L，et al.Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma：a randomized clinical trial[J]．J Cancer Res Clin Oncol，2006，132(7):458-65.
|
| 110 |
Nishiguchi S, Tamori A, Kubo S．Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma[J]．Intervirology，2005，48(1):71-5.
|
| 111 |
Mazzaferro V, Romito R, Schiavo M，et al.Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis[J]．Hepatology，2006，44(6):1543-54.
|
| 112 |
Ji J, Shi J, Budhu A，et al.MicroRNA expression，survival，and response to interferon in liver cancer[J]．N Engl J Med，2009，361(15):1437-47.
|
| 113 |
Bruix J, Takayama T, Mazzaferro V，et al.Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation(STORM)：a phase 3，randomised，double-blind，placebo-controlled trial[J]．Lancet Oncol，2015，16(13):1344-54.
|
| 114 |
Wang SN, Chuang SC, Lee KT.Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery：A pilot study[J]．Hepatol Res，2014，44(5):523-31.
|
| 115 |
Sapisochin G, Bruix J．Liver transplantation for hepatocellular carcinoma：outcomes and novel surgical approaches[J]．Nat Rev Gastroenterol Hepatol，2017，14(4):203-17.
|
| 116 |
Zheng SS, Xu X, Wu J，et al.Liver transplantation for hepatocellular carcinoma：Hangzhou experiences[J]．Transplantation，2008，85(12):1726-32.
|
| 117 |
Fan J, Yang GS, Fu ZR，et al.Liver transplantation outcomes in 1，078 hepatocellular carcinoma patients：a multi-center experience in Shanghai，China[J]．J Cancer Res Clin Oncol，2009，135(10):1403-12.
|
| 118 |
Li J, Yan LN, Yang J，et al.Indicators of prognosis after liver transplantation in Chinese hepatocellular carcinoma patients[J]．World J Gastroenterol，2009，15(33):4170-6.
|
| 119 |
邵卓，杨广顺，杨宁，等．三亚共识在原发性肝癌肝移植治疗中的运用[J]．中国实用外科杂志，2008，28(6):466-69.
|
| 120 |
Llovet JM, Pavel M, Rimola J，et al.Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria(Barcelona Clinic Liver Cancer extended criteria)[J]．Liver Transpl，2018，24(3):369-79.
|
| 121 |
Pinheiro RS, Waisberg DR, Nacif LS，et al.Living donor liver transplantation for hepatocellular cancer：an(almost)exclusive Eastern procedure？[J]．Transl Gastroenterol Hepatol，2017，2:68.
|
| 122 |
Sposito C, Cucchetti A, Mazzaferro V．Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma[J]．Dig Dis Sci，2019，64(4):1001-07.
|
| 123 |
Segev DL, Sozio SM, Shin EJ，et al.Steroid avoidance in liver transplantation：meta-analysis and meta-regression of randomized trials[J]．Liver Transpl，2008，14(4):512-25.
|
| 124 |
Rodriguez-Peralvarez M, Tsochatzis E, Naveas MC，et al.Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma[J]．J Hepatol，2013，59(6):1193-9.
|
| 125 |
Liang W, Wang D, Ling X，et al.Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma：a meta-analysis[J]．Liver Transpl，2012，18(1):62-9.
|
| 126 |
Zhou J, Wang Z, Wu ZQ，et al.Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria[J]．Transplant Proc，2008，40(10):3548-53.
|
| 127 |
Geissler EK, Schnitzbauer AA, Zulke C，et al.Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma：A Randomized，Multicenter，Open-Label Phase 3 Trial[J]．Transplantation，2016，100(1):116-25.
|
| 128 |
Thorat A, Jeng LB, Yang HR，et al.Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria：re-inventing the role of mammalian target of rapamycin inhibitors[J]．Ann Hepatobiliary Pancreat Surg，2017，21(4):205-11.
|
| 129 |
Filgueira NA.Hepatocellular carcinoma recurrence after liver transplantation：Risk factors，screening and clinical presentation[J]．World J Hepatol，2019，11(3):261-72.
|
| 130 |
Au KP, Chok KSH.Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma：A proposed management algorithm[J]．World J Gastroenterol，2018，24(45):5081-94.
|
| 131 |
Hasegawa K, Aoki T, Ishizawa T，et al.Comparison of the therapeutic outcomes between surgical resection and percutaneous ablation for small hepatocellular carcinoma[J]．Ann Surg Oncol，2014，21 Suppl 3:S348-55.
|
| 132 |
Li L, Zhang J, Liu X, Li X, Jiao B, Kang T．Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma：a meta-analysis[J]．J Gastroenterol Hepatol，2012，27(1):51-8.
|
| 133 |
Huang J, Yan L, Cheng Z，et al.A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria[J]．Ann Surg，2010，252(6):903-12.
|
| 134 |
Feng Q, Chi Y, Liu Y, Zhang L, Liu Q．Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma：a meta-analysis of 23 studies[J]．J Cancer Res Clin Oncol，2015，141(1):1-9.
|
| 135 |
Peng ZW, Zhang YJ, Chen MS，et al.Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma：a prospective randomized trial[J]．J Clin Oncol，2013，31(4):426-32.
|
| 136 |
Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K．Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma：a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization[J]．Cancer，2010，116(23):5452-60.
|
| 137 |
Chen QW, Ying HF, Gao S，et al.Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma：A systematic review and meta-analysis[J]．Clin Res Hepatol Gastroenterol，2016，40(3):309-14.
|
| 138 |
Peng ZW, Lin XJ, Zhang YJ，et al.Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller：a retrospective comparative study[J]．Radiology，2012，262(3):1022-33.
|
| 139 |
Livraghi T, Meloni F, Di Stasi M，et al.Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis：Is resection still the treatment of choice？[J]．Hepatology，2008，47(1):82-9.
|
| 140 |
Weis S, Franke A, Mossner J, Jakobsen JC, Schoppmeyer K．Radiofrequency(thermal)ablation versus no intervention or other interventions for hepatocellular carcinoma[J]．Cochrane Database Syst Rev，2013，(12):Cd003046.
|
| 141 |
Kim YS, Lim HK, Rhim H，et al.Ten-year outcomes of percutaneous radiofrequency ablation as first-line therapy of early hepatocellular carcinoma：analysis of prognostic factors[J]．J Hepatol，2013，58(1):89-97.
|
| 142 |
Zhang L, Ge NL, Chen Y，et al.Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma：10-year follow-up in Chinese patients[J]．Med Oncol，2015，32(3):77.
|
| 143 |
Cho YK, Kim JK, Kim MY, Rhim H, Han JK.Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies[J]．Hepatology，2009，49(2):453-9.
|
| 144 |
Shibata T, Iimuro Y, Yamamoto Y，et al.Small hepatocellular carcinoma：comparison of radio-frequency ablation and percutaneous microwave coagulation therapy[J]．Radiology，2002，223(2):331-7.
|
| 145 |
Di Vece F, Tombesi P, Ermili F, Maraldi C, Sartori S．Coagulation areas produced by cool-tip radiofrequency ablation and microwave ablation using a device to decrease back-heating effects：a prospective pilot study[J]．Cardiovasc Intervent Radiol，2014，37(3):723-9.
|
| 146 |
Ahmed M, Solbiati L, Brace CL，et al.Image-guided tumor ablation：standardization of terminology and reporting criteria--a 10-year update[J]．Radiology，2014，273(1):241-60.
|
| 147 |
Lencioni R, De Baere T, Soulen MC, Rilling WS, Geschwind JF.Lipiodol transarterial chemoembolization for hepatocellular carcinoma：A systematic review of efficacy and safety data[J]．Hepatology，2016，64(1):106-16.
|
| 148 |
Pelletier G, Ducreux M, Gay F，et al.Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization：a multicenter randomized trial.Groupe CHC[J]．J Hepatol，1998，29(1):129-34.
|
| 149 |
Lo CM, Ngan H, Tso WK，et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J]．Hepatology，2002，35(5):1164-71.
|
| 150 |
Llovet JM, Real MI, Montana X，et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma：a randomised controlled trial[J]．Lancet，2002，359(9319):1734-9.
|
| 151 |
Camma C, Schepis F, Orlando A，et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma：meta-analysis of randomized controlled trials[J]．Radiology，2002，224(1):47-54.
|
| 152 |
Llovet JM, Bruix J．Systematic review of randomized trials for unresectable hepatocellular carcinoma：Chemoembolization improves survival[J]．Hepatology，2003，37(2):429-42.
|
| 153 |
中华医学会放射学分会介入学组协作组．原发性肝细胞癌经导管肝动脉化疗性栓塞治疗技术操作规范专家共识[J]．中华放射学杂志，2011，45(10):908-12.
|
| 154 |
Yang M, Fang Z, Yan Z，et al.Transarterial chemoembolisation(TACE)combined with endovascular implantation of an iodine-125 seed strand for the treatment of hepatocellular carcinoma with portal vein tumour thrombosis versus TACE alone：a two-arm，randomised clinical trial[J]．J Cancer Res Clin Oncol，2014，140(2):211-9.
|
| 155 |
胡鸿涛，黎海亮，郭晨阳，等.125I粒子植入联合动脉化学栓塞治疗原发性肝癌合并门静脉癌栓[J]．中华放射学杂志，2012，46(6):552-56.
|
| 156 |
Si ZM, Wang GZ, Qian S，et al.Combination Therapies in the Management of Large(>/＝5 cm)Hepatocellular Carcinoma：Microwave Ablation Immediately Followed by Transarterial Chemoembolization[J]．J Vasc Interv Radiol，2016.
|
| 157 |
Jang JW, Choi JY, Bae SH，et al.Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma[J]．J Hepatol，2004，41(3):427-35.
|
| 158 |
Wahl DR, Stenmark MH, Tao Y，et al.Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma[J]．J Clin Oncol，2016，34(5):452-9.
|
| 159 |
Chino F, Stephens SJ, Choi SS，et al.The role of external beam radiotherapy in the treatment of hepatocellular cancer[J]．Cancer，2018，124(17):3476-89.
|
| 160 |
Shen PC, Chang WC, Lo CH，et al.Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma[J]．Int J Radiat Oncol Biol Phys，2019.
|
| 161 |
Hara K, Takeda A, Tsurugai Y，et al.Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation：A Propensity Score Analysis[J]．Hepatology，2019，69(6):2533-45.
|
| 162 |
Bujold A, Massey CA, Kim JJ，et al.Sequential phase I and Ⅱ trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma[J]．J Clin Oncol，2013，31(13):1631-9.
|
| 163 |
Su TS, Liang P, Liang J，et al.Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular Carcinoma[J]．Int J Radiat Oncol Biol Phys，2017，98(3):639-46.
|
| 164 |
Kim N, Kim HJ, Won JY，et al.Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma[J]．Radiother Oncol，2019，131:81-87.
|
| 165 |
Rim CH, Kim HJ, Seong J．Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma：A systematic review and meta-analysis of observational studies[J]．Radiother Oncol，2019，131:135-44.
|
| 166 |
Ohri N, Dawson LA, Krishnan S，et al.Radiotherapy for Hepatocellular Carcinoma：New Indications and Directions for Future Study[J]．J Natl Cancer Inst，2016，108(9).
|
| 167 |
Huo YR, Eslick GD.Transcatheter Arterial Chemoembolization Plus Radiotherapy Compared With Chemoembolization Alone for Hepatocellular Carcinoma：A Systematic Review and Meta-analysis[J]．JAMA Oncol，2015，1(6):756-65.
|
| 168 |
Zeng ZC, Tang ZY, Fan J，et al.A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma[J]．Cancer J，2004，10(5):307-16.
|
| 169 |
Meng MB, Cui YL, Lu Y，et al.Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma：a systematic review and meta-analysis[J]．Radiother Oncol，2009，92(2):184-94.
|
| 170 |
Yoon SM, Ryoo BY, Lee SJ，et al.Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion：A Randomized Clinical Trial[J]．JAMA Oncol，2018，4(5):661-69.
|
| 171 |
Shen L, Xi M, Zhao L，et al.Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion：Stereotactic Body Radiotherapy versus Sorafenib[J]．Cancers(Basel)，2018，10(12).
|
| 172 |
Zeng ZC, Fan J, Tang ZY，et al.A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus[J]．Int J Radiat Oncol Biol Phys，2005，61(2):432-43.
|
| 173 |
中华医学会放射肿瘤学分会，中国生物医学工程学会精确放疗分会肝癌学组与消化系统肿瘤专家委员会，中国研究型医院学会放射肿瘤学分会肝癌学组.2016年原发性肝癌放疗共识[J]．中华放射肿瘤学杂志，2016，25(11):1141-50.
|
| 174 |
Jihye C, Jinsil S．Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma[J]．Liver Cancer，2012，1(3-4):216-25.
|
| 175 |
Soliman H, Ringash J, Jiang H，et al.Phase Ⅱ trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases[J]．J Clin Oncol，2013，31(31):3980-6.
|
| 176 |
Wang WH, Wang Z, Wu JX，et al.Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels[J]．Liver Int，2015，35(12):2603-10.
|
| 177 |
Sapisochin G, Barry A, Doherty M，et al.Stereotactic body radiotherapy vs.TACE or RFA as a bridge to transplant in patients with hepatocellular carcinoma.An intention-to-treat analysis[J]．J Hepatol，2017，67(1):92-99.
|
| 178 |
Byun HK, Kim HJ, Im YR, Kim DY, Han KH, Seong J．Dose escalation by intensity modulated radiotherapy in liver-directed concurrent chemoradiotherapy for locally advanced BCLC stage C hepatocellular carcinoma[J]．Radiother Oncol，2019，133:1-8.
|
| 179 |
曾昭冲．肝细胞癌的立体定向放射治疗[J]．中华肿瘤杂志，2015，(9):650-52,53.
|
| 180 |
Hu Y, Zhou YK, Chen YX, Shi SM, Zeng ZC.4D-CT scans reveal reduced magnitude of respiratory liver motion achieved by different abdominal compression plate positions in patients with intrahepatic tumors undergoing helical tomotherapy[J]．Med Phys，2016，43(7):4335.
|
| 181 |
中华医学会核医学分会转移性骨肿瘤治疗工作委员会．氯化锶[89Sr]治疗转移性骨肿瘤专家共识(2017年版)[J]．中华核医学与分子影像杂志，2018，6(38):412-15.
|
| 182 |
Llovet JM, Ricci S, Mazzaferro V，et al.Sorafenib in advanced hepatocellular carcinoma[J]．N Engl J Med，2008，359(4):378-90.
|
| 183 |
Cheng AL, Kang YK, Chen Z，et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma：a phase Ⅲ randomised，double-blind，placebo-controlled trial[J]．Lancet Oncol，2009，10(1):25-34.
|
| 184 |
Pressiani T, Boni C, Rimassa L，et al.Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma：a prospective feasibility analysis[J]．Ann Oncol，2013，24(2):406-11.
|
| 185 |
Kudo M, Finn RS, Qin S，et al.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma：a randomised phase 3 non-inferiority trial[J]．Lancet，2018，391(10126):1163-73.
|
| 186 |
Qin S, Bai Y, Lim HY，et al.Randomized，multicenter，open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]．J Clin Oncol，2013，31(28):3501-8.
|
| 187 |
Qin S, Cheng Y, Liang J，et al.Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in Chinese patients with advanced hepatocellular carcinoma：a subgroup analysis of the EACH study[J]．Oncologist，2014，19(11):1169-78.
|
| 188 |
Assenat E, Pageaux GP, Thezenas S，et al.Sorafenib alone vs.sorafenib plus GEMOX as 1(st)-line treatment for advanced HCC：the phase Ⅱ randomised PRODIGE 10 trial[J]．Br J Cancer，2019，120(9):896-902.
|
| 189 |
屈凤莲，郝学志，秦叔逵，等．亚砷酸注射液治疗原发性肝癌的Ⅱ期多中心临床研究[J]．中华肿瘤杂志，2011，33(9):697-701.
|
| 190 |
Bruix J, Qin S, Merle P，et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE)：a randomised，double-blind，placebo-controlled，phase 3 trial[J]．Lancet，2017，389(10064):56-66.
|
| 191 |
El-Khoueiry AB, Sangro B, Yau T，et al.Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040)：an open-label，non-comparative，phase 1/2 dose escalation and expansion trial[J]．Lancet，2017，389(10088):2492-502.
|
| 192 |
Zhu AX, Finn RS, Edeline J，et al.Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224)：a non-randomised，open-label phase 2 trial[J]．Lancet Oncol，2018，19(7):940-52.
|
| 193 |
Brahmer JR, Lacchetti C, Schneider BJ，et al.Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy：American Society of Clinical Oncology Clinical Practice Guideline[J]．J Clin Oncol，2018，36(17):1714-68.
|
| 194 |
Haanen J, Carbonnel F, Robert C，et al.Management of toxicities from immunotherapy：ESMO Clinical Practice Guidelines for diagnosis，treatment and follow-up[J]．Ann Oncol，2018，29(Supplement_4):iv264-iv66.
|
| 195 |
Puzanov I, Diab A, Abdallah K，et al.Managing toxicities associated with immune checkpoint inhibitors：consensus recommendations from the Society for Immunotherapy of Cancer(SITC)Toxicity Management Working Group[J]．J Immunother Cancer，2017，5(1):95.
|
| 196 |
程树群，吴孟超，陈汉，等．胸腺肽α1对原发性肝癌术后复发的影响[J]．中华肝胆外科杂志，2004，10(9):592-93.
|
| 197 |
Wang Y, Chen M, Wu Z，et al.CD133-directed CAR T cells for advanced metastasis malignancies：A phase I trial[J]．Oncoimmunology，2018，7(7):e1440169.
|
| 198 |
Lee JH, Lee JH, Lim YS，et al.Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma[J]．Gastroenterology，2015，148(7):1383-91 e6.
|
| 199 |
Abou-Alfa GK, Meyer T, Cheng AL，et al.Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma[J]．N Engl J Med，2018，379(1):54-63.
|
| 200 |
Zhu AX, Park JO, Ryoo BY，et al.Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib(REACH)：a randomised，double-blind，multicentre，phase 3 trial[J]．Lancet Oncol，2015，16(7):859-70.
|
| 201 |
Zhu AX, Kang YK, Yen CJ，et al.Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations(REACH-2)：a randomised，double-blind，placebo-controlled，phase 3 trial[J]．Lancet Oncol，2019，20(2):282-96.
|
| 202 |
中华中医药学会．肿瘤中医诊疗指南[M]．北京：中国中医药出版社，2008：34-37.
|
| 203 |
阎涛，毕新宇，方仪，等．槐耳颗粒对原发性肝癌患者术后长期生存的影响[J]．中华肝胆外科杂志，2012，18(2):99-102.
|
| 204 |
成远，华海清．榄香烯治疗原发性肝癌的研究进展[J]．临床肿瘤学杂志，2017，22(10):950-53.
|
| 205 |
路大鹏，王玉强，赵卫林，等．康莱特联合肝动脉化疗栓塞术治疗肝癌的临床研究[J]．世界临床医学，2017，11(5):70,72.
|
| 206 |
高继良．肝复乐方剂治疗晚期原发性肝癌的前瞻性、随机对照临床研究[J]．中国中药杂志，2014，39(12):2367-69.
|
| 207 |
范隼，李庆源，周志涛，等．TACE联合金龙胶囊治疗原发性肝癌的效果研究[J]．中国实用医药，2019，14(21):42-44.
|
| 208 |
蔡文辉，尹春丽，范庆秋．艾迪联合肝动脉化疗栓塞术治疗中晚期原发性肝癌的临床观察[J]．中国医师杂志，2018，20(11):1723-25.
|
| 209 |
杨新华．TACE联合鸦胆子油乳液静脉滴注对肝癌患者的临床疗效及VEGF水平的影响[J]．海峡药学，2017，29(09):176-77.
|
| 210 |
彭文达．复方斑蝥胶囊联合化疗治疗中晚期原发性肝癌的临床疗效观察[J]．肿瘤药学，2011，1(06):518-19+43.
|
| 211 |
中华医学会感染病学分会，中华医学会肝病学分会．慢性乙型肝炎防治指南(2019年版)[J]．中华临床感染病杂志，2019，12(6):1674-2397.
|
| 212 |
中华医学会肝病学分会，中华医学会感染病学分会．丙型肝炎防治指南(2019年版)[J]．中华临床感染病杂志，2019，13(1):1-18.
|
| 213 |
European Association for the Study of the Liver.Electronic Address EEE，European Association for the Study of The L．EASL Recommendations on Treatment of Hepatitis C 2018[J]．J Hepatol，2018，69(2):461-511.
|
| 214 |
Seymour L, Bogaerts J, Perrone A，et al.iRECIST：guidelines for response criteria for use in trials testing immunotherapeutics[J]．Lancet Oncol，2017，18(3):e143-e52.
|
| 215 |
Yoshida H, Mamada Y, Taniai N, Uchida E．Spontaneous ruptured hepatocellular carcinoma[J]．Hepatol.Res.，2016，46(1):13-21.
|
| 216 |
Zhong F, Cheng XS, He K, Sun SB, Zhou J, Chen HM.Treatment outcomes of spontaneous rupture of hepatocellular carcinoma with hemorrhagic shock：a multicenter study[J]．Springerplus，2016，5(1):1101.
|
| 217 |
Moris D, Chakedis J, Sun SH，et al.Management，outcomes，and prognostic factors of ruptured hepatocellular carcinoma：A systematic review[J]．J Surg Oncol，2018，117(3):341-53.
|
| 218 |
Sahu SK, Chawla YK, Dhiman RK，et al.Rupture of Hepatocellular Carcinoma：A Review of Literature[J]．J Clin Exp Hepatol，2019，9(2):245-56.
|
| 219 |
Aoki T, Kokudo N, Matsuyama Y，et al.Prognostic impact of spontaneous tumor rupture in patients with hepatocellular carcinoma：an analysis of 1160 cases from a nationwide survey[J]．Ann Surg，2014，259(3):532-42.
|
| 220 |
Lai EC, Lau WY.Spontaneous rupture of hepatocellular carcinoma：a systematic review[J]．Arch Surg，2006，141(2):191-8.
|
| 221 |
Shin BS, Park MH, Jeon GS.Outcome and prognostic factors of spontaneous ruptured hepatocellular carcinoma treated with transarterial embolization[J]．Acta Radiol，2011，52(3):331-5.
|
| 222 |
Zhou J, Huang A, Yang XR.Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma[J]．J Gastrointest Cancer，2016，47(2):157-67.
|
| 223 |
Guo W, Sun YF, Shen MN，et al.Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis，Prognosis，and Therapeutic Response Evaluation in Hepatocellular Carcinoma[J]．Clin Cancer Res，2018，24(9):2203-13.
|
| 224 |
Zhou Y, Wang B, Wu J，et al.Association of preoperative EpCAM Circulating Tumor Cells and peripheral Treg cell levels with early recurrence of hepatocellular carcinoma following radical hepatic resection[J]．BMC Cancer，2016，16:506.
|
| 225 |
Sun YF, Xu Y, Yang XR，et al.Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection[J]．Hepatology，2013，57(4):1458-68.
|
| 226 |
Guo W, Yang XR, Sun YF，et al.Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform[J]．Clin Cancer Res，2014，20(18):4794-805.
|
| 227 |
Sun YF, Guo W, Xu Y，et al.Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma[J]．Clin Cancer Res，2018，24(3):547-59.
|
| 228 |
Qu C, Wang Y, Wang P，et al.Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy[J]．Proc Natl Acad Sci U S A，2019，116(13):6308-12.
|
| 229 |
Huang A, Zhang X, Zhou SL，et al.Plasma Circulating Cell-free DNA Integrity as a Promising Biomarker for Diagnosis and Surveillance in Patients with Hepatocellular Carcinoma[J]．J Cancer，2016，7(13):1798-803.
|
| 230 |
Huang A, Zhao X, Yang XR，et al.Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma[J]．J Hepatol，2017，67(2):293-301.
|
| 231 |
Huang A, Zhang X, Zhou SL，et al.Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity[J]．J Cancer，2016，7(13):1907-14.
|
| 232 |
Cai J, Chen L, Zhang Z，et al.Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma[J]．Gut，2019，68(12):2195-205.
|
| 233 |
Li W, Zhang X, Lu X，et al.5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers[J]．Cell Res，2017，27(10):1243-57.
|
| 234 |
Llovet JM, Montal R, Sia D, Finn RS.Molecular therapies and precision medicine for hepatocellular carcinoma[J]．Nat Rev Clin Oncol，2018，15(10):599-616.
|
| 235 |
Gao Q, Zhu H, Dong L，et al.Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma[J]．Cell，2019，179(2):561-77 e22.
|
| 236 |
Jiang Y, Sun A, Zhao Y，et al.Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma[J]．Nature，2019，567(7747):257-61.
|
| 237 |
Torbenson MS，Ng IOL，Park YN，Roncalli M，Sakamato M，WHO classification of digestive system tumor 5th edition，Geneva，Switzerland：World Health Organization：229-39.
|
| 238 |
Shi J, Lai EC, Li N，et al.Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus[J]．Ann Surg Oncol，2010，17(8):2073-80.
|
| 239 |
Liver Cancer Study Group of Japan.General rules for the clinical and pathological study of primary liver cancer[M].2nd English ed.Tokyo：Kanehara，2003.
|
| 240 |
Lyu N, Lin Y, Kong Y，et al.FOXAI：a phase Ⅱ trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]．Gut，2018，67(2):395-96.
|
| 241 |
Lyu N, Kong Y, Mu L，et al.Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorinvs.sorafenib for advanced hepatocellular carcinoma[J]．J Hepatol，2018，69(1):60-69.
|
| 242 |
He M, Li Q, Zou R，et al.Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin，Fluorouracil，and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion：A Randomized Clinical Trial[J]．JAMA Oncol，2019，5(7):953-60.
|
| 243 |
Lyu N, Kong Y, Pan T，et al.Hepatic Arterial Infusion of Oxaliplatin，Fluorouracil，and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread[J]．J Vasc Interv Radiol，2019，30(3):349-57 e2.
|
| 244 |
Wang Q, Xia D, Bai W，et al.Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma：A multicentre observational study[J]．J Hepatol，2019，70(5):893-903.
|
| 245 |
Xu L, Peng ZW, Chen MS，et al.Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization[J]．J Hepatol，2015，63(1):122-30.
|
| 246 |
Kudo M, Ueshima K, Ikeda M，et al.Randomised，multicentre prospective trial of transarterial chemoembolisation(TACE)plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma：TACTICS trial[J]．Gut，2019.
|
| 247 |
Marks LB, Yorke ED, Jackson A，et al.Use of normal tissue complication probability models in the clinic[J]．Int J Radiat Oncol Biol Phys，2010，76(3 Suppl):S10-9.
|
| 248 |
Pan CC, Kavanagh BD, Dawson LA，et al.Radiation-associated liver injury[J]．Int J Radiat Oncol Biol Phys，2010，76(3 Suppl):S94-100.
|
| 249 |
Chon YE, Seong J, Kim BK，et al.Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma：endoscopic findings and risk factors[J]．Int J Radiat Oncol Biol Phys，2011，81(5):1343-51.
|
| 250 |
Hanna GG, Murray L, Patel R，et al.UK Consensus on Normal Tissue Dose Constraints for Stereotactic Radiotherapy[J]．Clin Oncol(R Coll Radiol)，2018，30(1):5-14.
|
| 251 |
Cheng AL，Qin S，Ikeda M．IMbrave150：Efficacy and Safety Results From a Ph 3 Study Evaluating Atezolizumab(atezo)＋ Bevacizumab(bev)vs Sorafenib(Sor)as First Treatment(tx)for Patients(pts)With Unresectable Hepatocellular Carcinoma(HCC)[C].2019 ESMO Asia：LBA03.
|
| 252 |
Xu J, Zhang Y, Jia R，et al.Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma，Gastric，or Esophagogastric Junction Cancer：An Open-label，Dose Escalation and Expansion Study[J]．Clin Cancer Res，2019，25(2):515-23.
|